Nebacumab
Jump to navigation
Jump to search
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | endotoxin |
Clinical data | |
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
(what is this?) (verify) |
Nebacumab is a human monoclonal antibody developed for the treatment of sepsis.[1] It has been withdrawn in 1993 because it failed to reduce mortality in clinical trials.[2]
References
- ^ Derkx B, Wittes J, McCloskey R (April 1999). "Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group". Clinical Infectious Diseases. 28 (4): 770–7. doi:10.1086/515184. PMID 10825037.
- ^ WHO: Consolidated List of Products
Categories:
- Articles with short description
- Short description is different from Wikidata
- Articles with changed CASNo identifier
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugs that are a monoclonal antibody
- Monoclonal antibodies
- Withdrawn drugs
- Abandoned drugs
- All stub articles
- Antiinfective agent stubs
- Monoclonal antibody stubs